Plasminogen activator inhibitor type-1 (Part one): Basic mechanisms, regulation, and role for thromboembolic disease

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 3, 2001, Pages 183-193

  Huber, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

PAI 1; Regulation; Thromboembolic disease

Indexed keywords

ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ESTROGEN; GEMFIBROZIL; INSULIN; METFORMIN; NICOTINIC ACID; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADIPOSE TISSUE; ARTERY THROMBOSIS; BLOOD LEVEL; CIRCULATION; CONCENTRATION (PARAMETERS); CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; FIBRINOLYSIS; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART INFARCTION; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; METABOLIC PARAMETERS; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANIMALS; FIBRINOLYSIS; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN-ANGIOTENSIN SYSTEM; THROMBOEMBOLISM;

EID: 0035169759     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011955018052     Document Type: Review

References (180)

1. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: An update
2. Detection of plasminogen activator-inhibitor-1 (PAI-1) mRNA in human megakaryocytes by in situ hybridization
3. Platelets inhibit fibrinolysis in vitro by both plasminogen activator-dependent and -independent mechanisms
4. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in the thrombolysis resistance: Studies with thrombi generated in the Chandler loop
5. Plasminogen activator inhibitor (PAI-1) in plasma and platelets
6. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene
7. Calcium-dependent stabilization of type-1 plasminogen activator inhibitor within platelet alpha-granules
8. Visceral fat accumulation and its relation to plasma haemostatic factors in healthy men
9. Production of plasminogen activator inhibitor-1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease
10. The adipocyte and hemostatic balance in obesity. Studies of PAI-1
11. Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells
12. Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells
13. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease
14. Cell-associated plasminogen activation: Regulation and physiologic function
15. A new life-long hemorrhagic disorder due to excess plasminogen activator
16. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level
17. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1
18. Brief report: Complete deficiency of plasminogen activator inhibitor type 1 due to a frame shift mutation
19. The status of PAI-1 as a risk factor for arterial and thrombotic disease
20. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease
21. Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction
22. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis
23. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity
24. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
25. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study
26. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene
27. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene
28. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non insulin-dependent diabetes mellitus
29. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants
30. 4G/5G promoter PAI-1 gene polymorphism is associated with plasmatic PAI-1 activity in Italians: A model of gene-environment interaction
31. Gene polymorphisms for PAI-1 are associated with the angiographic extent of coronary artery disease
32. Allele specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
33. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
34. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease
35. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease
36. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism
37. A common 4G allele in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency
38. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
39. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentration: A family study with part of the Stanislas Cohort
40. Diabetes and atherosclerosis: An epidemiologic view
41. Hypertension and associated metabolic abnormalities: The role of insulin resistance and the sympathoadrenal system
42. Insulin resistance and coronary heart disease
43. Hyperinsulinemia as an independent risk factor for ischemic heart disease
44. Hypofibrinolysis and insulin resistance
45. Hyperlipoproteinemia and reduced fibrinolytic activity in healthy coronary high risk men
46. Metformin decreases the high plasminogen activator inhibitor capacity plasma insulin and triglyceride levels in non diabetic obese subjects
47. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease
48. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: Relationship to the metabolic cardiovascular syndrome
49. Hypertriglyceridemia and regulation of fibrinolytic activity
50. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
51. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: Studies in randomly selected normo- and hypertriglyceridemic men
52. Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1500 patients with angina pectoris
53. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men
54. Insulin sensitivity is not an independent determinant of plasminogen activator inhibitor-1 activity
55. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: The Northern Sweden MONICA study
56. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction
57. Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension
58. Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction
59. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2
60. Plasminogen activator inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
61. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
62. Augmentation of synthesis of plasminogen activator inhibitor1 by insulin and insulin-like growth factor type 1: Implications for vascular disease in hyperinsulinemic states
63. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor
64. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells
65. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis
66. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease
67. Upregulation of PAI-1 synthesis by insulin and proinsulin in HepG2 cells but not in endothelial cells
68. Remnant-like particle cholesterol in coronary artery disease: Correlation with plasminogen activator inhibitor-1 activity
69. Plasminogen activator inhibitor-1 antigen concentration during insulin and oral glucose tolerance tests in obese men
70. Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease
71. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo
72. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance
73. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. A potential factor predisposing to thrombosis and its persistance
74. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control
75. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients
76. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors
77. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol
78. Doxazosin effects on insulin and glucose in hypertensive patients
79. Glucose, insulin, and lipid metabolism in doxazosin treated patients with hypertension
80. Effects of doxazosin, a selective alpha-1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension
81. Doxazosin improves insulin sensitivity in hypertensive patients
82. Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters
83. Effects of gemfibrozil on lipids and haemostasis after myocardial infraction
84. Direct effects of gemfibrozil on the fibrinolytic system
85. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy
86. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis
87. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells
88. HMG-CoA reductase inhibitors affect the fibrinolytic system of human smooth muscle cells in vitro
89. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells
90. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study
91. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease
92. The activation of plasminogen activator inhibitor-1 expression by IL-1β is attenuated by estrogen in hepatoblastoma hepG2 cells expressing estrogen receptors
93. Reduced fibrinolytic response in obese children: Association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1)
94. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: Induction by tumor necrosis factor-alpha and lipopolysaccharide
95. Elaboration of type-1 plasminogen activator inhibitor from adipocytes: A potential pathogenetic link between obesity and cardiovascular disease
96. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
97. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
98. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals
99. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue
100. Impact of weight lost on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults
101. Amelioration of the inhibition of fibrinolysis in the elderly, obese subjects by moderate energy intake restriction
102. PAI-1, obesity, insulin resistance and risk of cardiovascular events
103. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss
104. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II - Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
105. Angiotensin II increases plasminogen activator inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells
106. Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells
107. Stimulation of tissue-type plasminogen activator in vivo by infusion of bradykinin
108. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells
109. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells
110. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV
111. Role of the angiotensin AT receptor in rat aortic and cardiac PAI-1 gene expression
112. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounts for half of the variance of serum enzyme levels
113. Angiotensin I-converting enzyme in the human circulating mononuclear cells: Genetic polymorphism of expression in T lymphocytes
114. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
115. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction
116. Plasminogen activator inhibitor 1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward - Relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes
117. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction
118. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
119. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction
120. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction
121. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1
122. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure
123. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension
124. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension
125. Comparative cross-over study of the effects of lisinopril and doxazosin on insulin, glucose and lipoprotein metabolism and the endogenous fibrinolytic system
126. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: Effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors
127. Angiotensin-converting enzyme inhibition suppress plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta
128. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat
129. The insulin resistance syndrome in smokers is related to smoking habits
130. Dietary regulation of fibrinolytic factors
131. Effects of exercise training on plasminogen activator inhibitor activity
132. Fibrinolytic and hemostatic parameter response after resistance exercise
133. The role of the fibrinolytic system in deep venous thrombosis
134. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism
135. Hypofibrinolysis and venous thrombosis
136. Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism
137. Postoperative changes in the plasmatic level of tissue-type plasminogen activator and its fast-acting inhibitor: Relationship to deep vein thrombosis and influence of prophylaxis
138. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis
139. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene
140. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with primary pulmonary hypertension
141. Chronic thromboembolic pulmonary hypertension
142. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension
143. Mechanisms contributing to the stabilization of chronic pulmonary thromboemboli: Prevalence of type 1 plasminogen activator inhibitor (PAI-1) expression in the pulmonary vasculature
144. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli
145. Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism
146. Synthesis and localization of PAI-1 in the vessel wall
147. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombosis
148. Platelets stimulate endothelial cells to synthesize type-1 plasminogen activator inhibitor
149. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
150. Plasminogen activator inhibitor in blood of patients with coronary artery disease
151. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction
152. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
153. Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis
154. Plasminogen activator inhibitor-1 and atherothrombosis
155. The relationship between impaired fibrinolysis and coronary heart disease
156. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study
157. Tissue-type plasminogen activator and type-1 plasminogen activator inhibitor in patients with coronary artery disease: Relations to clinical variables and cardiovascular risk factors
158. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischemic heart disease
159. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities
160. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women
161. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
162. Circadian variation in the frequency of onset of acute myocardial infarction
163. Circadian variation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
164. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)
165. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
166. The 4G/4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease
167. PAI-1 gene polymorphism in patients with coronary artery disease and malignant ventricular arrhythmias
168. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly
169. Plasminogen activator inhibitor type-1 (part two): Role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents
170. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis
171. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: A potential progenitor of restenosis
172. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients
173. Untersuchung zur frage von persistierenden veränderungen der fibrinolyseparameter t-PA und PAI bei patienten nach juvenilem ischämischem cerebralem insult
174. Tissue plasminogen activator and plasminogen activator inhibitor 1 in stroke patients
175. Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Discrimination between individuals with and without a history of ischemic stroke
176. Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease
177. Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease
178. Fibrinolytic activity in peripheral atherosclerosis in the elderly